Doublet chemotherapy in the elderly patient with ovarian cancer

Oncologist

Volumn 17, Issue 11, 2012, Pages 1450-1460

  Teo, Min Y ^a   Power, Derek G ^a   Tew, William P ^b   Lichtman, Stuart M ^c  

^a Department of Medicine National University of Ireland Cork   (Ireland)

^b Gynecologic Medical Oncology Service   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Elderly; Geriatrics; Ovarian cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; MITOXANTRONE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TOPOTECAN; TRABECTEDIN; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; AGGRESSION; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; COLLOID CARCINOMA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GERIATRIC ASSESSMENT; GERIATRIC PATIENT; GRANULOCYTOPENIA; HUMAN; HYPERTENSION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SKIN BLEEDING; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOXICITY; TREATMENT RESPONSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CLINICAL TRIALS AS TOPIC; FEMALE; GERIATRIC ASSESSMENT; HUMANS; INJECTIONS, INTRAPERITONEAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 84869430640     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0155     Document Type: Article

References (104)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-2529.
2. Merino MJ, Jaffe G. Age contrast in ovarian pathology. Cancer 1993;71:537-544.
3. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA: Cancer J Clin 2008;58:71-96.
4. American Cancer Society. Cancer Facts & Figures, 2010. Atlanta, GA: American Cancer Society; 2010.
5. Barnholtz-Sloan JS, Schwartz AG, Qureshi F et al. Ovarian cancer: Changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 2003;189:1120-1127.
6. Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993;71:517-523.
7. Markman M, Lewis JL, Saigo P et al. Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1993;71:634-637.
8. Grover SA, Cook EF, Adam J, Coupal L, Goldman L. Delayed diagnosis of gynecologic tumors in elderly women: Relation to national medical practice patterns. Am J Med 1989;86:151-157.
9. Moore DH, Kauderer JT, Bell J et al. An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: A Gynecologic Oncology Group study. Gynecol Oncol 2004;94:368-374.
10. Pectasides D, Fountzilas G, Aravantinos G et al. Epithelial ovarian carcinoma in younger vs. older women: Is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. Int J Gynecol Cancer 2007;17:1003-1010.
11. Vercelli M, Capocaccia R, Quaglia A, et-al. Relative survival in elderly European cancer patients: Evidence for health care inequalities. The EUROCARE Working Group. Crit Rev Oncol Hematol 2000;35:161-179.
12. Winter WE, Maxwell GL, Tian C et al. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007;25:3621-3627.
13. Trimbos JB, Parmar M, Vergote I et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95:105-112.
14. Aabo K, Adams M, Adnitt P et al. Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998;78:1479-1487.
15. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
16. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study. J Clin Oncol 2000;18:106-115.
17. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial ofcisplatin-paclitaxel versus cispla-tin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 2000;92:699-708.
18. McGuire WP, Markman M. Primary ovarian cancer chemotherapy: Current standards of care. Br J Cancer 2003;89(Suppl 3):S3-S8.
19. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084-3092.
20. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-3200.
21. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/ paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-1329.
22. Greimel ER, Bjelic-Radisic V, Pfisterer J et al. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carbopla-tin/paclitaxel. J Clin Oncol 2006;24:579-586.
23. du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management ofovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference. Ann Oncol 2005;16 (Suppl 8):7-12.
24. Hilpert F, du Bois A, Greimel ER et al. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged ≥70 years with advanced ovarian cancer: A study by the AGO OVAR Germany. Ann Oncol 2007;18:282-287.
25. Yoneda J, Kuniyasu H, Crispens MA et al. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl CancerInst 1998;90:447-454.
26. Garcia AA, Hirte H, Fleming G et al. Phase II Clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 2008;26:76-82.
27. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-2483.
28. Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-2496.
29. ICON Collaborators. ICON2: Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. International Collaborative Ovarian Neoplasm Study. Lancet 1998;352:1571-1576.
30. International Collaborative Ovarian Neoplasm G. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 2002;360: 505-515.
31. Pignata S, Monfardini S. Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma. Eur J Cancer 2000;36: 817-820.
32. Nicoletto MO, Artioli G, Donach M et al. Elderly ovarian cancer: Treatment with mitoxantrone-carbopla-tin. Gynecol Oncol 2001;80:221-226.
33. Thigpen T, Brady MF, Omura GA et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 1993;71:606-614.
34. Tredan O, Geay JF, Touzet S et al. Carboplatin/ cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Ann Oncol 2007;18:256-262.
35. Bicher A, Sarosy G, Kohn E et al. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer 1993;71:594-600.
36. Ries LA. Ovarian cancer. Survival and treatment differences by age. Cancer 1993;71:524-529.
37. Munoz KA, Harlan LC, Trimble EL. Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 1997;15:3408-3415.
38. Harlan LC, Clegg LX, Trimble EL. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 2003;21: 3488-3494.
39. Sundararajan V, Hershman D, Grann VR et al. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: A population-based study. J Clin Oncol 2002;20:173-178.
40. Hershman D, Jacobson JS, McBride R et al. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol 2004;94:540-549.
41. Petignat P, Fioretta G, Verkooijen HM et al. Poorer survival of elderly patients with ovarian cancer: A population-based study. Surg Oncol 2004;13:181-186.
42. Maas HA, Kruitwagen RF, Lemmens VE et al. The influence of age and comorbidity on treatment and prognosis of ovarian cancer: A population-based study. Gynecol Oncol 2005;97:104-109.
43. Carney ME, Lancaster JM, Ford C et al. A population-based study of patterns of care for ovarian cancer: Who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 2002;84:36-42.
44. Krzyzanowska MK, Regan MM, Powell M et al. Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer. J Am Coll Surg 2009;208:202-209.
45. Hurria A, Naeim A, Elkin E et al. Adjuvant treatment recommendations in older women with breast cancer: A survey of oncologists. Crit Rev Oncol Hematol 2007;61:255-260.
46. Brand AH. Ovarian cancer debulking surgery: A survey of practice in Australia and New Zealand. Int J Gynecol Cancer 2011;21:230-235.
47. Foster JA, Salinas GD, Mansell D et al. How does older age influence oncologists' cancer management? The Oncologist 2010;15:584-592.
48. Balducci L, Extermann M. Management of cancer in the older person: A practical approach. The Oncolo-gist 2000;5:224-237.
49. Ceccaroni M, D'Agostino G, Ferrandina G et al. Gynecological malignancies in elderly patients: Is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. Gynecol Oncol 2002;85:445-450.
50. Eisenhauer EL, Tew WP, Levine DA et al. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol 2007;106:381-387.
51. Higgins RV, Naumann RW, Gardner J, Hall JB. Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin? Gynecol Oncol 1999;75:464-467.
52. Kotani N, Katsumata N, Yonemori K et al. P61 Feasibility, efficacy and toxicity of carboplatin and pac-litaxel as a first-line treatment in elderly patients with ovarian cancer. Crit Rev Oncol Hematol 2009;72:S40.
53. Bruchim I, Altaras M, Fishman A. Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecologic Oncol 2002; 86:274-278.
54. Penson RT, Kornblith B, Lee J, et al. Phase II study of carboplatin and paclitaxel in elderly women with newly diagnosed ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 2008;26(15 suppl):5590.
55. Fader AN, von Gruenigen V, Gibbons H et al. Improved tolerance of primary chemotherapy with re-duced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol 2008;109:33-38.
56. Furini L, Artioli G, Lombardi G et al. P49 Chemotherapy in older women with ovarian cancer. Crit Rev Oncol Hematol 2009;72:S36.
57. Mackay HJ, Brady MF, Oza AM et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010;20:945-952.
58. Bamias A, Psaltopoulou T, Sotiropoulou M et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer 2010;116:1462-1468.
59. Yahata T, Banzai C, Tanaka K. Histology-specific long-term trends in the incidence of ovarian cancer and borderline tumor in Japanese females: A population-based study from 1983 to 2007 in Niigata. J Obstet Gynaecol Res 2012;38:645-650.
60. Chan JK, Teoh D, Hu JM et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008;109:370-376.
61. Marchetti DL, Lele SB, Priore RL et al. Treatment of advanced ovarian carcinoma in the elderly. Gynecol Oncol 1993;49:86-91.
62. Alberts DS, Dahlberg S, Green SJ et al. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer 1993;71:618-627.
63. Edmonson JH, Su J, Krook JE. Treatment of ovarian cancer in elderly women. Mayo Clinic-North Central Cancer Treatment Group studies. Cancer 1993;71:615-617.
64. Gershenson DM, Mitchell MF, Atkinson N et al. Age contrasts in patients with advanced epithelial ovarian cancer. The MD Anderson Cancer Center experience. Cancer 1993;71:638-643.
65. Katsumata N, Yasuda M, Takahashi F et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:1331-1338.
66. Bookman MA, Brady MF, McGuire WP et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009;27: 1419-1425.
67. Tew W, Java J, Chi D, et al. Treatment outcomes for older women with advanced ovarian cancer: Results from a phase III clinical trial (GOG182). J Clin Oncol 2010;28(15 suppl):5030.
68. Guarneri V, Piacentini F, Barbieri E, Conte PF. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol 2010;117:152-158.
69. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-1955.
70. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
71. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus pacli-taxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-1007.
72. Kothari R, Nagel C, Koopmeiners JS et al. The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer. Gynecol Oncol 2010;119:491-495.
73. Tew W, O'Cearbhaill R, Zhou Q et al. Intraperitoneal chemotherapy (IPC) in older women with epithelial ovarian cancer (EOC). J Clin Oncol 2009;27(15 suppl): 5541.
74. Launay-Vacher V, Spano JP, Janus N et al. Renal insufficiency and anticancer drugs in elderly cancer patients: A subgroup analysis of the IRMA study. Crit Rev Oncol Hematol 2009;70:124-133.
75. Lichtman SM, Wildiers H, Launay-Vacher V et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007;43:14-34.
76. Lichtman SM, Hollis D, Miller AA et al. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 2006;24:1846-1851.
77. Tew WP, Lichtman SM. Ovarian cancer in older women. Semin Oncol 2008;35:582-589.
78. Markman M, Bookman MA. Second-line treatment of ovarian cancer. The Oncologist 2000;5:26-35.
79. Parmar MK, Ledermann JA, Colombo N et al. Pac-litaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-2106.
80. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:4699-4707.
81. Aghajanian C, Blank SV, Goff BA et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-2045.
82. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28:3323-3329.
83. Kurtz J, Hilpert F, Dorum A, et al. Can elderly patients with recurrent ovarian cancer (ROC) be treated with a platinum-based doublet? Results from the CALYPSO trial. J Clin Oncol 2010;28(15 suppl):5031.
84. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010;28:3107-3114.
85. Markman M. Pharmaceutical management of ovarian cancer: Current status. Drugs 2008;68:771-789.
86. Gronlund B, Hogdall C, Hansen HH, Engelholm SA. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer 2002;94:1961-1967.
87. Pignata S, Ferrandina G, Scarfone G et al. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: Results from the SOCRATES retrospective study. Crit Rev Oncol Hematol 2009;71: 233-241.
88. Orimo H, Ito H, Suzuki T et al. Reviewing the definition of "elderly." Geriatr Gerontol Intl 2006;6:149-158.
89. Chan JK, Loizzi V, Lin YG et al. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol 2003;102:156-161.
90. Cress RD, O'Malley CD, Leiserowitz GS, Cample-man SL. Patterns of chemotherapy use for women with ovarian cancer: A population-based study. J Clin Oncol 2003;21:1530-1535.
91. Moore KN, Reid MS, Fong DN et al. Ovarian cancer in the octogenarian: Does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol 2008;110:133-139.
92. Hightower RD, Nguyen HN, Averette HE et al. National survey of ovarian carcinoma. IV: Patterns of care and related survival for older patients. Cancer 1994;73:377-383.
93. Walter LC, Covinsky KE. Cancer screening in elderly patients: A framework for individualized decision making. JAMA 2001;285:2750-2756.
94. Pentheroudakis G, Fountzilas G, Kalofonos HP et al. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. Crit Rev Oncol He-matol 2008;66:237-247.
95. Uyar D, Frasure HE, Markman M, von Gruenigen VE. Treatment patterns by decade of life in elderly women (70 years of age) with ovarian cancer. Gynecol Oncol 2005;98:403-408.
96. Villella JA, Chaudhry T, Pearl ML et al. Comparison of tolerance of combination carboplatin and pacli-taxel chemotherapy by age in women with ovarian cancer. Gynecol Oncol 2002;86:316-322.
97. Repetto L, Fratino L, Audisio RA et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol 2002;20:494-502.
98. Monfardini S, Ferrucci L, Fratino L et al. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 1996;77:395-401.
99. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25:1824-1831.
100. Hurria A, Togawa K, Mohile SG et al. Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 2011;29: 3457-3465.
101. Chaïbi P, MagneN, Breton S, et al. Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients. Crit Rev Oncol Hematol 2010;79: 302-307.
102. Aaldriks A, Maartense E, le Cessie S, et al. Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy. Crit Rev Oncol Hematol 2010;79:205-212.
103. Pignata S, Breda E, Scambia G et al. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol 2008;66:229-236.
104. Freyer G, Geay JF, Touzet S et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: A GINECO study. Anna Oncol 2005;16: 1795-1800.